NXTS Nexentis Technologies Inc.
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NXTS
—
—
What changed
Recent filings, trades and moves- Nov 10 8-K: Unregistered share sale
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 9
- List Date
- 2009-12-15
- CIK
- 0001789192
- Headquarters
- New York, NY
- Homepage
- https://nexentistech.com
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -9.48% | -9.48% |
| Mar | -32.84% | -32.84% |
| Apr | 3.62% | 3.62% |
| May | 20.13% | 20.13% |
| Jun | -16.80% | -16.80% |
| Jul | -61.66% | -61.66% |
| Aug | -13.04% | -13.04% |
| Sep | -21.02% | -21.02% |
| Oct | -59.07% | -59.07% |
| Nov | -16.82%* | -16.82% |
| Dec | -- | -- |
| Total | -94.36% | -94.36% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.71
SMA 50: $4.97
SMA 200: —
Current: $2.21
EMA 12: $2.55
EMA 26: $3.31
MACD: -0.7615 | Signal: 0.1041
BEARISH
ADX (14): 35.05
TREND
+DI: 11.66
−DI: 30.62
Momentum Oscillators
RSI (14): 29.64
OVERSOLD
Stoch %K: 9.04
Stoch %D: 12.84
Williams %R: -85.93
Volume & Volatility
BB Upper: $3.34
BB Lower: $2.08
NEUTRAL
OBV: 8,723,888
Vol SMA 20: 55,981
Vol ROC: -77.38%
ATR: $0.48
True Range: $0.21
HV 20: 124.0%
HV 30: 137.1%
HV 60: 106.1%
Data Summary
Data Points: 182
Last Updated:
Date Range: 2026-02-26T00:00:00 – 2026-11-13T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All NXTS news →
NXTS Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Put vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put
—
—
pts
EXTREME
ATM — / Put —
30 DTE / 10d put
—
—
pts
EXTREME
ATM — / Put —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.4090
Alpha: -221.20%
Correlation: 0.0900
R-Squared: 0.8%
Stock Volatility: 226.4%
Market Volatility: 14.5%
Analysis Details
Benchmark: SPY
Data Points: 181
Period: 252 trading days
Data Points: 181
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
NXTS Institutional Ownership (13F)
Filings for 2026-06-30 · 2 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
NXTS Board & Officers
As of SEC filings through Oct 22, 2026Directors 6
- Amitay Weiss · since Aug 26, 2020
- Israel Yakov Berenstein · since Aug 26, 2020
- Ronen Rosenbloom · since Aug 26, 2020
- Eliahou Arbib · since Jan 12, 2021
- Liat Sidi · since Nov 12, 2023
- Asaf Itzhaik · since Dec 20, 2023
Officers 3
- David Palach · Chief Executive Officer · since Nov 5, 2020
- Lital Barda · Chief Financial Officer · since Apr 17, 2022
- Shlomo Zakai · Controller · listed since Feb 2026
10% owners 3
- Alon Silberman · since Oct 20, 2025
- Eun Young Lee · since Jan 22, 2026
- SciSparc Ltd. (entity) · since Oct 20, 2025
Changes in the last 10 years (29)
| Feb 11, 2026 | Shlomo Zakai listed as Controller (previously Chief Financial Officer) in SEC filings |
| Jan 22, 2026 | Eun Young Lee became a 10% owner |
| Oct 20, 2025 | SciSparc Ltd. became a 10% owner |
| Oct 20, 2025 | Alon Silberman became a 10% owner |
| Dec 20, 2023 | Asaf Itzhaik became a director |
| Dec 15, 2023 | The company announced the departure of Roy Borochov from the board in an SEC filing |
| Nov 12, 2023 | Liat Sidi became a director |
| Jul 27, 2023 | Yaaran Investments Ltd. became a 10% owner |
| Apr 5, 2023 | Roy Borochov became a director |
| Apr 5, 2023 | Plantify Foods, Inc. became a 10% owner |
| Jan 23, 2023 | The company announced the departure of Neta Matis as COO of the Issuer's Subsidiary in an SEC filing |
| Apr 18, 2022 | The company announced the departure of Omri Kanterovich as Interim CFO in an SEC filing |
| Apr 17, 2022 | Lital Barda became Chief Financial Officer |
| Jan 31, 2022 | Neta Matis became COO of the Issuer's Subsidiary |
| Jan 18, 2022 | Omri Kanterovich became Interim CFO |
| Jan 12, 2022 | Mia Jacqueline Serra became Chief Marketing Officer |
| May 18, 2021 | Udi Ovadia Kalifi became a director |
| Jan 12, 2021 | Eliahou Arbib became a director |
| Nov 5, 2020 | David Palach became Chief Executive Officer |
| Aug 26, 2020 | Ronen Rosenbloom became a director |
| Aug 26, 2020 | Israel Yakov Berenstein became a director |
| Aug 26, 2020 | Amitay Weiss became a director |
| Jul 15, 2020 | Joachim Fuchs became a director |
| Nov 25, 2019 | Yaakov Jacob Perry became a director |
| Nov 25, 2019 | Vered Raz-Avayo became a director |
| Nov 25, 2019 | Shlomo Zakai became Chief Financial Officer |
| Nov 25, 2019 | Doron Shorrer became a director |
| Nov 25, 2019 | Dan Sztybel became Chief Executive Officer |
| Nov 25, 2019 | Benad Goldwasser became a director |
Not reported recently (10)
- Udi Ovadia Kalifi · Last reported as a director in an SEC filing dated Dec 26, 2024
- Yaaran Investments Ltd. · Last reported as a 10% owner in an SEC filing dated Aug 1, 2023
- Plantify Foods, Inc. · Last reported as a 10% owner in an SEC filing dated Apr 10, 2023
- Mia Jacqueline Serra · Last reported as Chief Marketing Officer in an SEC filing dated Jan 28, 2022
- Benad Goldwasser · Last reported as a director in an SEC filing dated Sep 29, 2020
- Dan Sztybel · Last reported as Chief Executive Officer in an SEC filing dated Aug 18, 2020
- Yaakov Jacob Perry · Last reported as a director in an SEC filing dated Aug 18, 2020
- Vered Raz-Avayo · Last reported as a director in an SEC filing dated Aug 18, 2020
- Joachim Fuchs · Last reported as a director in an SEC filing dated Aug 18, 2020
- Doron Shorrer · Last reported as a director in an SEC filing dated Dec 23, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-10
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-10 | Unregistered share sale | EDGAR |
| 2026-11-06 | Shareholder rights change · Bylaws or fiscal year change · Other events | EDGAR |
| 2026-10-19 | Unregistered share sale · Director or officer change | EDGAR |
| 2026-10-06 | Material agreement | EDGAR |
| 2026-09-03 | Listing standards notice | EDGAR |
| 2026-08-06 | Auditor change | EDGAR |
| 2026-06-22 | Material agreement · Unregistered share sale | EDGAR |
| 2026-06-12 | Material agreement · Unregistered share sale | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-13 | 0001493152-26-037757 | EDGAR |
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
NXTS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.27T | 46.9 | +45.5% | +33.6% | 17 |
| JNJ Johnson & Johnson | $682.5B | 43.4 | +7.8% | +37.8% | 65 |
| ABBV ABBVIE INC. | $520.5B | 50.8 | +10.7% | +28.7% | 26 |
| MRK Merck & Co., Inc. | $362.3B | 152.3 | +4.9% | +38.8% | 32 |
| NVS Novartis AG | $302.7B | — | — | +15.9% | 36 |
| AZN AstraZeneca PLC | $286.0B | — | — | +101.4% | 0 |
| ABT Abbott Laboratories | $185.8B | 40.2 | +10.0% | −12.6% | 14 |
| NVO Novo-Nordisk A/S | $179.2B | — | — | −20.5% | 2 |
| NXTS Nexentis Technologies Inc. Common Stock | $1M | — | — | −93.9% | — |
| Peer median | $332.5B | 46.9 | +10.0% | +31.1% | 22 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.